J&J unit advances Addex's compound into depression trial; NYT on the history of leukemia treatment;

 @FierceBiotech: Check out this special report by @MarkHFierce: Stem cell research advances in fits and starts. Report | Follow @FierceBiotech

 @JohnCFierce: Pazdur talks up the new wave of cancer drug apps (20) headed to the FDA this year. Expects rising number of approvals. More | Follow @JohnCFierce

 @RyanMFierce: My report on 5 next-gen software tools for biopharma R&D. Report | Follow @RyanMFierce

> Addex Therapeutics says that its partner Janssen Research & Development, a unit of Johnson & Johnson ($JNJ), plans to advance Addex's compound ADX71149 to a Phase II trial as a potential treatment for adults with major depression and anxiety symptoms. Item

> The New York Times charted progress in leukemia treatment. Article

> Auxilium Pharmaceuticals hopes that Pfizer ($PFE) will exercise an option on its drug as a treatment for penile curvature after the drug beat placebo in a study. Report

> Emergent BioSolutions has garnered $8.4 million in funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to test BioThrax as an anthrax vaccine for use on people before they are exposed to the deadly toxin. News

Pharma News

 @FiercePharma: Abbott unveils exec team to back up pharma spinoff CEO Richard Gonzalez--Dow JonesMore | Follow @FiercePharma

> Appeals court reinstates KV investors' $1.5B lawsuit. More

> ASCO lobbies for fines to combat drug shortages. Story

> Some drug recalls slip through FDA-reporting cracks. Article

> Reports: Pfizer to cut 180 jobs at two Irish plants. News

Medical Devices News

 @FierceMedDev: Only a few weeks left to submit your nominations for the 15 fiercest private device developers. Survey | Follow @FierceMedDev

> Biomet mulls dental division spin-off. Article

> Awarepoint snags $14M to expand RFIDs for hospitals. More

> Neuronetics gets CE mark for depression-treating device. Story

> Auxogyn reels in $18M to fuel IVF/embryo viability test. News

Biotech Research News

> Cellular changes explain greater breast cancer risk in older women. Story

> Novel technique helps detail Parkinson's modus operandi. Article

> U.K. scientists detect cancer from stray DNA fragments in blood. More

> Synthetic peptide helps defeat recurrent cancer's resistance to treatment. News

Pharma Manufacturing News

> Lipitor losses lead to Pfizer headcount reduction in Ireland. More

> FDA fails to send alerts on 20% of Class I drug recalls. Article

> Court says KV Pharma shareholders have every right to sue. Story

And Finally… Secretive and influential: Data safety monitoring boards play a key role in the drug-development business. Article

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.